SK282873B6 - Izolovaná molekula nukleovej kyseliny, funkčný fragment melanómového polypeptidu gp75, polypeptid, expresný vektor, ich použitie a vakcíny - Google Patents
Izolovaná molekula nukleovej kyseliny, funkčný fragment melanómového polypeptidu gp75, polypeptid, expresný vektor, ich použitie a vakcíny Download PDFInfo
- Publication number
- SK282873B6 SK282873B6 SK760-91A SK76091A SK282873B6 SK 282873 B6 SK282873 B6 SK 282873B6 SK 76091 A SK76091 A SK 76091A SK 282873 B6 SK282873 B6 SK 282873B6
- Authority
- SK
- Slovakia
- Prior art keywords
- polypeptide
- melanoma
- atgg
- vaccine
- functional fragment
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 36
- 229960005486 vaccine Drugs 0.000 title claims abstract description 30
- 201000001441 melanoma Diseases 0.000 title claims description 70
- 102100030310 5,6-dihydroxyindole-2-carboxylic acid oxidase Human genes 0.000 title 1
- 101000773083 Homo sapiens 5,6-dihydroxyindole-2-carboxylic acid oxidase Proteins 0.000 title 1
- 201000011510 cancer Diseases 0.000 claims abstract description 33
- 239000012634 fragment Substances 0.000 claims abstract description 32
- 238000004519 manufacturing process Methods 0.000 claims abstract description 26
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 18
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 18
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 18
- 230000002708 enhancing effect Effects 0.000 claims abstract description 8
- 230000004936 stimulating effect Effects 0.000 claims abstract description 8
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 67
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 59
- 229920001184 polypeptide Polymers 0.000 claims description 50
- 239000002299 complementary DNA Substances 0.000 claims description 29
- 239000002671 adjuvant Substances 0.000 claims description 22
- 239000003937 drug carrier Substances 0.000 claims description 20
- 239000013604 expression vector Substances 0.000 claims description 16
- 239000013598 vector Substances 0.000 claims description 13
- 230000028993 immune response Effects 0.000 claims description 12
- 102100039819 Actin, alpha cardiac muscle 1 Human genes 0.000 claims description 6
- 101000959247 Homo sapiens Actin, alpha cardiac muscle 1 Proteins 0.000 claims description 6
- FVFVNNKYKYZTJU-UHFFFAOYSA-N 6-chloro-1,3,5-triazine-2,4-diamine Chemical compound NC1=NC(N)=NC(Cl)=N1 FVFVNNKYKYZTJU-UHFFFAOYSA-N 0.000 claims description 5
- 101100476480 Mus musculus S100a8 gene Proteins 0.000 claims description 5
- 244000299461 Theobroma cacao Species 0.000 claims description 5
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 claims description 5
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 claims description 5
- 235000001046 cacaotero Nutrition 0.000 claims description 5
- 239000002773 nucleotide Substances 0.000 claims description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 4
- 230000002147 killing effect Effects 0.000 claims description 4
- 125000003729 nucleotide group Chemical group 0.000 claims description 4
- 102100039217 3-ketoacyl-CoA thiolase, peroxisomal Human genes 0.000 claims description 3
- 241000726103 Atta Species 0.000 claims description 3
- 101100153048 Homo sapiens ACAA1 gene Proteins 0.000 claims description 3
- 102100029812 Protein S100-A12 Human genes 0.000 claims description 3
- 101710110949 Protein S100-A12 Proteins 0.000 claims description 3
- CUJRVFIICFDLGR-UHFFFAOYSA-N acetylacetonate Chemical compound CC(=O)[CH-]C(C)=O CUJRVFIICFDLGR-UHFFFAOYSA-N 0.000 claims description 3
- CJWXCNXHAIFFMH-AVZHFPDBSA-N n-[(2s,3r,4s,5s,6r)-2-[(2r,3r,4s,5r)-2-acetamido-4,5,6-trihydroxy-1-oxohexan-3-yl]oxy-3,5-dihydroxy-6-methyloxan-4-yl]acetamide Chemical compound C[C@H]1O[C@@H](O[C@@H]([C@@H](O)[C@H](O)CO)[C@@H](NC(C)=O)C=O)[C@H](O)[C@@H](NC(C)=O)[C@@H]1O CJWXCNXHAIFFMH-AVZHFPDBSA-N 0.000 claims description 3
- 241000700618 Vaccinia virus Species 0.000 claims description 2
- 230000010076 replication Effects 0.000 claims description 2
- 241001123946 Gaga Species 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 6
- 108020004414 DNA Proteins 0.000 abstract description 2
- 102000053602 DNA Human genes 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 29
- 239000000427 antigen Substances 0.000 description 26
- 102000036639 antigens Human genes 0.000 description 26
- 108091007433 antigens Proteins 0.000 description 26
- 108090000623 proteins and genes Proteins 0.000 description 21
- 210000002752 melanocyte Anatomy 0.000 description 19
- 102000004169 proteins and genes Human genes 0.000 description 17
- 210000002966 serum Anatomy 0.000 description 15
- 150000001413 amino acids Chemical class 0.000 description 14
- 230000004069 differentiation Effects 0.000 description 9
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 102000003886 Glycoproteins Human genes 0.000 description 7
- 108090000288 Glycoproteins Proteins 0.000 description 7
- 101000606090 Homo sapiens Tyrosinase Proteins 0.000 description 7
- 208000012641 Pigmentation disease Diseases 0.000 description 7
- 239000007983 Tris buffer Substances 0.000 description 7
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 7
- 230000019612 pigmentation Effects 0.000 description 7
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 7
- 108010051815 Glutamyl endopeptidase Proteins 0.000 description 6
- 241001529936 Murinae Species 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 5
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 238000010367 cloning Methods 0.000 description 5
- 230000003834 intracellular effect Effects 0.000 description 5
- 208000021039 metastatic melanoma Diseases 0.000 description 5
- 238000012163 sequencing technique Methods 0.000 description 5
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 5
- VUFNLQXQSDUXKB-DOFZRALJSA-N 2-[4-[4-[bis(2-chloroethyl)amino]phenyl]butanoyloxy]ethyl (5z,8z,11z,14z)-icosa-5,8,11,14-tetraenoate Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)OCCOC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 VUFNLQXQSDUXKB-DOFZRALJSA-N 0.000 description 4
- 101000608782 Mus musculus Tyrosinase Proteins 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 238000001114 immunoprecipitation Methods 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 108010062580 Concanavalin A Proteins 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 3
- 108060008724 Tyrosinase Proteins 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 239000012133 immunoprecipitate Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000002751 oligonucleotide probe Substances 0.000 description 3
- 238000012510 peptide mapping method Methods 0.000 description 3
- 230000001376 precipitating effect Effects 0.000 description 3
- 230000017854 proteolysis Effects 0.000 description 3
- 238000000539 two dimensional gel electrophoresis Methods 0.000 description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 101100480489 Arabidopsis thaliana TAAC gene Proteins 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000829958 Homo sapiens N-acetyllactosaminide beta-1,6-N-acetylglucosaminyl-transferase Proteins 0.000 description 2
- 208000003367 Hypopigmentation Diseases 0.000 description 2
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 2
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 2
- 102100023315 N-acetyllactosaminide beta-1,6-N-acetylglucosaminyl-transferase Human genes 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 102100036049 T-complex protein 1 subunit gamma Human genes 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 102000003425 Tyrosinase Human genes 0.000 description 2
- 206010047642 Vitiligo Diseases 0.000 description 2
- 101150062912 cct3 gene Proteins 0.000 description 2
- 230000006957 competitive inhibition Effects 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 230000003425 hypopigmentation Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000002780 melanosome Anatomy 0.000 description 2
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- IVLXQGJVBGMLRR-UHFFFAOYSA-N 2-aminoacetic acid;hydron;chloride Chemical compound Cl.NCC(O)=O IVLXQGJVBGMLRR-UHFFFAOYSA-N 0.000 description 1
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 1
- 101001025146 Bartonella bacilliformis Cell division protein FtsZ Proteins 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 1
- 206010064912 Malignant transformation Diseases 0.000 description 1
- 101100154912 Mus musculus Tyrp1 gene Proteins 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 101000895926 Streptomyces plicatus Endo-beta-N-acetylglucosaminidase H Proteins 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 238000003277 amino acid sequence analysis Methods 0.000 description 1
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- VDQQXEISLMTGAB-UHFFFAOYSA-N chloramine T Chemical compound [Na+].CC1=CC=C(S(=O)(=O)[N-]Cl)C=C1 VDQQXEISLMTGAB-UHFFFAOYSA-N 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 238000010230 functional analysis Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000001894 hemadsorption Effects 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 210000004754 hybrid cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000006058 immune tolerance Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000026045 iodination Effects 0.000 description 1
- 238000006192 iodination reaction Methods 0.000 description 1
- JDNTWHVOXJZDSN-UHFFFAOYSA-N iodoacetic acid Chemical compound OC(=O)CI JDNTWHVOXJZDSN-UHFFFAOYSA-N 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000036212 malign transformation Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000008099 melanin synthesis Effects 0.000 description 1
- 229940115256 melanoma vaccine Drugs 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 210000004694 pigment cell Anatomy 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y110/00—Oxidoreductases acting on diphenols and related substances as donors (1.10)
- C12Y110/03—Oxidoreductases acting on diphenols and related substances as donors (1.10) with an oxygen as acceptor (1.10.3)
- C12Y110/03001—Catechol oxidase (1.10.3.1), i.e. tyrosinase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0055—Oxidoreductases (1.) acting on diphenols and related substances as donors (1.10)
- C12N9/0057—Oxidoreductases (1.) acting on diphenols and related substances as donors (1.10) with oxygen as acceptor (1.10.3)
- C12N9/0059—Catechol oxidase (1.10.3.1), i.e. tyrosinase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
- C12Y114/16—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with reduced pteridine as one donor, and incorporation of one atom of oxygen (1.14.16)
- C12Y114/16002—Tyrosine 3-monooxygenase (1.14.16.2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
- C12Y114/18—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with another compound as one donor, and incorporation of one atom of oxygen (1.14.18)
- C12Y114/18001—Tyrosinase (1.14.18.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US49743190A | 1990-03-22 | 1990-03-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SK282873B6 true SK282873B6 (sk) | 2003-01-09 |
Family
ID=23976841
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK760-91A SK282873B6 (sk) | 1990-03-22 | 1991-03-21 | Izolovaná molekula nukleovej kyseliny, funkčný fragment melanómového polypeptidu gp75, polypeptid, expresný vektor, ich použitie a vakcíny |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US6168946B1 (da) |
| EP (2) | EP0965640A1 (da) |
| JP (2) | JP3336006B2 (da) |
| AT (1) | ATE187493T1 (da) |
| AU (1) | AU660412B2 (da) |
| CA (1) | CA2078773C (da) |
| CZ (1) | CZ290278B6 (da) |
| DE (1) | DE69131829T2 (da) |
| DK (1) | DK0522078T3 (da) |
| ES (1) | ES2141089T3 (da) |
| FI (1) | FI113786B (da) |
| GR (1) | GR3032804T3 (da) |
| HK (1) | HK1014732A1 (da) |
| HU (1) | HU218416B (da) |
| IE (2) | IE20000918A1 (da) |
| NO (1) | NO311366B1 (da) |
| NZ (1) | NZ237532A (da) |
| PL (3) | PL169168B1 (da) |
| PT (1) | PT97103B (da) |
| SK (1) | SK282873B6 (da) |
| WO (1) | WO1991014775A1 (da) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE20000918A1 (en) * | 1990-03-22 | 2001-05-30 | Sloan Kettering Inst Cancer | GP75 As a Tumor Vaccine for Melanoma |
| US7041801B1 (en) * | 1995-06-07 | 2006-05-09 | Vanderbilt University | Antibodies binding to polypeptides encoded by developmentally-regulated endothelial cell locus-1 |
| US5840839A (en) * | 1996-02-09 | 1998-11-24 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein |
| US7015312B1 (en) | 1996-02-09 | 2006-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Antibodies to the protein product encoded by ORF3 of the TRP-1 gene and compositions and kits thereof |
| US7001600B1 (en) | 1996-02-09 | 2006-02-21 | The United States Of America As Represented By The Secretary Of Health And Human Services | Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes |
| US6083703A (en) * | 1996-02-09 | 2000-07-04 | The United States Of America As Represented By The Department Of Health And Human Services | Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes |
| AU2001241533A1 (en) * | 2000-02-15 | 2001-08-27 | The Regents Of The University Of California | A universal vaccine and method for treating cancer employing telomerase reverse transcriptase |
| US6613534B2 (en) | 2001-03-20 | 2003-09-02 | Wake Forest University Health Sciences | MAP-2 as a determinant of metastatic potential |
| US20030113919A1 (en) * | 2001-08-17 | 2003-06-19 | Aventis Pasteur, Ltd. | Immunogenic targets for melanoma |
| US20030157720A1 (en) * | 2002-02-06 | 2003-08-21 | Expression Technologies Inc. | Protein standard for estimating size and mass |
| WO2008156655A2 (en) | 2007-06-15 | 2008-12-24 | Genelux Corporation | Vaccinia virus vectors encoding a sodium-dependent transporter protein for imaging and/or treatment of tumors |
| MX2010010021A (es) | 2008-03-12 | 2011-02-15 | Imclone Llc | Anticuepos anti-tyrp1. |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2504010B1 (fr) * | 1981-04-15 | 1985-10-25 | Sanofi Sa | Medicaments anticancereux contenant la chaine a de la ricine associee a un anticorps antimelanome et procede pour leur preparation |
| US4808704A (en) * | 1981-09-30 | 1989-02-28 | Sloan-Kettering Institute For Cancer Research | Monoclonal antibodies to cell surface antigens of human malignant melanoma |
| US4806628A (en) * | 1982-11-30 | 1989-02-21 | Sloan-Kettering Institute For Cancer Research | Monoclonal antibodies against melanocytes |
| US4591572A (en) * | 1983-04-01 | 1986-05-27 | Sloan-Kettering Institute For Cancer Research | Pigmentation associated, differentiation antigen of human melanoma and autologous antibody |
| USH819H (en) * | 1984-04-30 | 1990-09-04 | The United States Of America As Represented By The Secretary Of Energy | Palladium-109 labeled anti-melanoma monoclonal antibodies |
| US4851510A (en) * | 1984-11-30 | 1989-07-25 | Wadley Technologies, Inc. | Monoclonal antibodies to novel melanoma-associated antigens |
| US4798790A (en) * | 1985-07-18 | 1989-01-17 | Sloan-Kettering Institute | Monoclonal antibody specific for a pigmentation associated antigen |
| US5141742A (en) * | 1986-02-07 | 1992-08-25 | Oncogen | Vaccines against melanoma |
| US5262177A (en) * | 1986-02-07 | 1993-11-16 | Oncogen | Recombinant viruses encoding the human melanoma-associated antigen |
| US5009995A (en) * | 1986-10-27 | 1991-04-23 | Sloan-Kettering Institute For Cancer Research | Monoclonal antibodies to melanoma cells |
| US5059523A (en) * | 1988-05-02 | 1991-10-22 | Sloan-Kettering Institute For Cancer Research | Cell-surface glycoproteins of human sarcomas |
| US5009495A (en) * | 1989-05-26 | 1991-04-23 | Williams Robert D | Hinge for eyeglasses |
| EP1006194A3 (en) | 1989-08-04 | 2008-07-02 | Triton Biosciences Inc. | C-erbB-2 external domain: GP75 |
| IE20000918A1 (en) * | 1990-03-22 | 2001-05-30 | Sloan Kettering Inst Cancer | GP75 As a Tumor Vaccine for Melanoma |
| US5262117A (en) * | 1990-10-12 | 1993-11-16 | Centro Sviluppo Settori Impiego S.R.L. | Process for preparing thermoinsulating and/or structural formed articles and products so obtained |
| US6180604B1 (en) * | 1996-08-21 | 2001-01-30 | Micrologix Biotech Inc. | Compositions and methods for treating infections using analogues of indolicidin |
-
1991
- 1991-03-12 IE IE20000918A patent/IE20000918A1/en not_active IP Right Cessation
- 1991-03-12 IE IE082091A patent/IE910820A1/en not_active IP Right Cessation
- 1991-03-21 PT PT97103A patent/PT97103B/pt not_active IP Right Cessation
- 1991-03-21 NZ NZ237532A patent/NZ237532A/xx unknown
- 1991-03-21 SK SK760-91A patent/SK282873B6/sk unknown
- 1991-03-21 CZ CS1991760A patent/CZ290278B6/cs not_active IP Right Cessation
- 1991-03-22 PL PL91307930A patent/PL169168B1/pl not_active IP Right Cessation
- 1991-03-22 PL PL91289550A patent/PL168235B1/pl not_active IP Right Cessation
- 1991-03-22 EP EP99109256A patent/EP0965640A1/en not_active Withdrawn
- 1991-03-22 EP EP91908003A patent/EP0522078B1/en not_active Revoked
- 1991-03-22 ES ES91908003T patent/ES2141089T3/es not_active Expired - Lifetime
- 1991-03-22 PL PL91307929A patent/PL169105B1/pl not_active IP Right Cessation
- 1991-03-22 DE DE69131829T patent/DE69131829T2/de not_active Revoked
- 1991-03-22 HU HU9203009A patent/HU218416B/hu unknown
- 1991-03-22 AU AU76906/91A patent/AU660412B2/en not_active Ceased
- 1991-03-22 CA CA002078773A patent/CA2078773C/en not_active Expired - Fee Related
- 1991-03-22 JP JP50783191A patent/JP3336006B2/ja not_active Expired - Fee Related
- 1991-03-22 AT AT91908003T patent/ATE187493T1/de not_active IP Right Cessation
- 1991-03-22 DK DK91908003T patent/DK0522078T3/da active
- 1991-03-22 WO PCT/US1991/001942 patent/WO1991014775A1/en not_active Application Discontinuation
-
1992
- 1992-09-21 NO NO19923659A patent/NO311366B1/no unknown
- 1992-09-21 FI FI924222A patent/FI113786B/fi active
-
1995
- 1995-03-24 US US08/409,794 patent/US6168946B1/en not_active Expired - Lifetime
-
1998
- 1998-12-28 HK HK98116009A patent/HK1014732A1/xx not_active IP Right Cessation
-
2000
- 2000-02-29 GR GR20000400507T patent/GR3032804T3/el not_active IP Right Cessation
-
2001
- 2001-12-25 JP JP2001391870A patent/JP2002241314A/ja active Pending
-
2004
- 2004-06-25 US US10/877,489 patent/US20050037462A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Vijayasaradhi et al. | The melanoma antigen gp75 is the human homologue of the mouse b (brown) locus gene product. | |
| Takahara et al. | Type I procollagen COOH-terminal proteinase enhancer protein: identification, primary structure, and chromosomal localization of the cognate human gene (PCOLCE) | |
| AU701105B2 (en) | Colon cell and colon cancer cell associated nucleic acid molecules, protein and peptides | |
| Radu et al. | Nup155 is a novel nuclear pore complex protein that contains neither repetitive sequence motifs nor reacts with WGA. | |
| SK282873B6 (sk) | Izolovaná molekula nukleovej kyseliny, funkčný fragment melanómového polypeptidu gp75, polypeptid, expresný vektor, ich použitie a vakcíny | |
| Lau et al. | Evidence that heart connexin43 is a phosphoprotein | |
| KR19990087802A (ko) | 전립선암의 면역치료 및 면역진단을 위한 화합물 및 방법 | |
| US6180362B1 (en) | Peptides which inhibit ras protein activity, their preparation and use | |
| US7906616B2 (en) | Truncated DANCE, DANCE complex and method of using these | |
| US20050089941A1 (en) | Receptor of the EDb-fibronectin domains | |
| Cohen-Solal et al. | Identification and characterization of mouse Rab32 by mRNA and protein expression analysis | |
| CA2437535C (fr) | Polynucleotide utilisable pour moduler la proliferation des cellules cancereuses | |
| JP2002511271A (ja) | 新規膜メタロプロテアーゼｎｅｐｉｉ及び治療において有用な阻害因子のスクリーニングのためのその使用 | |
| US5741890A (en) | Protein binding fragments of gravin | |
| Kishore et al. | Development and characterization of mouse anti‐human LMP2, LMP7, TAP1 and TAP2 monoclonal antibodies | |
| Kamei et al. | Solh, the mouse homologue of the Drosophila melanogaster small optic lobes gene: organization, chromosomal mapping, and localization of gene product to the olfactory bulb | |
| JPH07309900A (ja) | 抗ヒトプロカテプシンｂモノクローナル抗体、それを産生するハイブリドーマ及びそれを用いたヒトプロカテプシンｂ又はヒトカテプシンｂの測定方法 | |
| US20040234959A1 (en) | Truncated bard1 protein, and its diagnostic and therapeutic uses | |
| JP4037451B2 (ja) | 大腸細胞および大腸癌細胞関連核酸分子、タンパク質およびペプチド | |
| JPH08510135A (ja) | ヒトカルシウムセンサー | |
| Kageshita et al. | Development and characterization of mouse anti-human LMP2, LMP7, TAPl and TAP2 monoclonal antibodies | |
| JP2002000274A (ja) | 新規遺伝子及びそれにコードされる蛋白質 | |
| JPH08322576A (ja) | プロテアソームアクチベーター | |
| JP2001327295A (ja) | 新規ヒトダクサス遺伝子及びそれにコードされる蛋白質 | |
| JP2008515797A (ja) | オスの避妊標的物としてのｔｓｓｋファミリーメンバーおよびｔｓｋｓの評価 |